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Abstract: Excessive complement activation is involved in the pathogenesis of many diseases and
the kidney is an organ with particular susceptibility to complement-mediated injury. Apart from
paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), there
are several other diseases with clear evidence of complement activation affecting both maternal and
fetal kidneys during pregnancy and causing long-term adverse outcomes. Several novel drugs have
been recently developed for blocking the complement cascade, including purified plasma proteins,
new monoclonal antibodies, recombinant proteins, small molecules, and small interfering RNA
agents. Eculizumab, the humanized monoclonal IgG2/4-antibody targeting C5 was approved by the
United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for
treatment of two rare diseases: PNH in 2007 and aHUS in 2011. There is an increasing number of
publications of successful use of eculizumab for off-label indications, e.g., in pregnant women with
antiphospholipid syndrome, sickle-cell anemia, and HELLP syndrome. These severe diseases are
associated with both high maternal and fetal morbidity and mortality rate and substantial prematurity.
Eculizumab has considerably improved overall outcome of patients with PNH and aHUS, enabling
safe pregnancy for many women. Prolongation of pregnancy and the use of eculizumab, even for only
a few weeks, may protect not only maternal renal function, but also alleviate acute and long-term
renal consequences of prematurity in offspring.
Keywords: eculizumab; pregnancy; premature birth; paroxysmal nocturnal hemoglobinuria; atypical
hemolytic uremic syndrome; antiphospholipid syndrome; sickle-cell anemia; HELLP; fetal kidney
development; complement activation
1. Introduction
Pregnancy is a unique and complex biological phenomenon with tremendous changes occurring,
particularly in the maternal cardiovascular system, immune system, and kidneys [1], with the term
birth of fetus with normal growth as the successful end-points. The immune system undergoes
significant adaptations during pregnancy in order to ensure survival of the fetal allograft and protect
mother and fetus from external threats.
An intact complement system is of essential importance for the successful maintenance of normal
pregnancy and is involved in both host defence and appropriate placental and fetal development.
Occasionally, excessive activation of complement may result in severe adverse pregnancy outcomes [2].
Maternal kidneys have high capacity for adaptation during the pregnancy [1]. However, despite
the significant improvements in obstetrical and neonatal care, burden of pregnancy, underlying
maternal chronic diseases, or specific pregnancy-specific diseases may jeopardize renal function,
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affecting not only the mother, but also fetus and neonate, mainly due to sequelae of iatrogenic
premature birth [3,4]. Kidney size and nephron number are significantly reduced in premature infants
(Figure 1).
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 2 of 20 
 
affecting not only the mother, but also fet s an  neonate, ainly due to sequelae of iatrogenic 
premature birth [3,4]. Kidney size a d nephron number are significantly re uced in premature 
infants (Figure 1). 
 
Figure 1. Kidney of a stillborn fetus with intrauterine growth restriction at 22 weeks of gestation. Note 
subcapsular (C) nephrogenic zone (encircled) with proliferating tubules (black arrows). Immature 
bilobed glomeruli (asterisks) lined by epithelial cells. Magnification 200×, hematoxylin-eosin staining. 
Scale bar 100 um. Courtesy: Dr. Jouko Lohi, Department of Pathology, Helsinki University Hospital, 
Finland. 
Furthermore, apart from the preterm birth, hostile intrauterine environment and aggressive 
neonatal treatments in extremely preterm survivors frequently cause long-term health consequences 
extending to adulthood including impaired neonatal renal function [5]. 
There are several diseases characterized by extensive complement activation, which is further 
triggered by the pregnancy. The kidney is an organ that is particularly susceptible to complement-
mediated injury. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic 
syndrome (aHUS) were historically diseases in which presence pregnancy was discouraged due to 
the poor outcome and life-threatening complications with substantial maternal and fetal/neonatal 
morbidity and mortality [4–7]. 
Eculizumab, the humanized monoclonal IgG2/4-antibody targeting C5, was approved by the 
United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for 
the treatment of paroxysmal nocturnal hemoglobinuria in 2007 and atypical hemolytic uremic 
syndrome in 2011 for treatment of these two rare diseases. Its use has significantly improved the 
outcome of both diseases, also in pregnant patients. 
Whilst the majority of publications on eculizumab use in clinical practice involved PNH and 
aHUS non-pregnant patients, there is a paucity of knowledge of eculizumab use in pregnant patients, 
especially in diseases with off-label eculizumab use (antiphospholipid syndrome, sickle-cell anemia, 
and preeclampsia/HELLP syndrome) (Table 1). Additionally, most of the publications have been 
focused on maternal, but not on fetal and neonatal outcome. 
Prolongation of pregnancy, even for only a few weeks could improve not only maternal renal 
function, but also alleviate renal consequences of prematurity in offspring. 
The purpose of this narrative review is to update relevant recent literature on eculizumab use in 
“classical” diseases related to the complement activation (PNH and aHUS) in non-pregnant patients, 
and to focus on its use in pregnant women affected PNH and aHUS with special emphasis on the 
adverse renal outcomes in mothers and their offspring. 
We will particularly focus on renal consequences of the premature birth that affect a substantial 
proportion of women not only with PNH and aHUS, but also antiphospholipid syndrome, sickle-cell 
anemia, and preeclampsia/HELLP syndrome. 
Figure 1. Kidney of a stillborn fet s it i tra teri e r t restricti at 22 weeks of gestation. Note
subcapsular (C) nephrogenic zone (encircle ) it roliferati t b les (black arro s). Immature
bilobed glomeruli (asterisks) lined by epithelial cells. agnification 200 , hematoxylin-eosin staining.
Scale bar 100 u . Courtesy: Dr. Jouko Lohi, Department of Pathology, Helsinki University
Hospital, Finland.
Furthermore, apart fro the preter i t rine environment and a gre sive
neonatal treatments in extremely preter se long-term health consequences
extending to adultho d including i paired e t l .
There are eral diseases characterized by extensive co plement activation, whic is
fu ther triggered by the pregnancy. The kidney is an o gan that is particularly susceptible
to complement-mediated injury. Paroxys al noct rnal hemoglobinuria (PNH) and atypical
hemolytic-uremic syndrome (aHUS) were historically diseases in which presence pregnancy was
discouraged due to the poor outcome and life-threatening complications with substantial maternal
and fetal/neonatal morbidity and mortality [4–7].
Eculizumab, the humanized monoclonal IgG2/4-antibody targeting C5, was approved by the
United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
for the treatment of paroxysmal nocturnal hemoglobinuria in 2007 and atypical hemolytic uremic
syndrome in 2011 for treatment of these two rare diseases. Its use has significantly improved the
outcome of both diseases, also in pregnant patients.
Whilst the majority of publications on eculizumab use in clinical practice involved PNH and
aHUS non-pregnant patients, there is a paucity of knowledge of eculizumab use in pregnant patients,
especially in diseases with off-label eculizumab use (antiphospholipid syndrome, sickle-cell anemia,
and preeclampsia/HELLP syndrome) (Table 1). Additionally, most of the publications have been
focused on maternal, but not on fetal and neonatal outcome.
Prolongation of pregnancy, even for only a few weeks could improve not only maternal renal
function, but also alleviate renal consequences of prematurity in offspring.
The purpose of this narrative review is to update relevant recent literature on eculizumab use in
“classical” diseases related to the complement activation (PNH and aHUS) in non-pregnant patients,
and to focus on its use in pregnant women affected PNH and aHUS with special emphasis on the
adverse renal outcomes in mothers and their offspring.
We will particularly focus on renal consequences of the premature birth that affect a substantial
proportion of women not only with PNH and aHUS, but also antiphospholipid syndrome, sickle-cell
anemia, and preeclampsia/HELLP syndrome.
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Table 1. Key references demonstrating complement activation in antiphospholipid syndrome, sickle-cell disease, and HELLP syndrome (potential extended indications
for eculizumab use).
Disease Subject(s) Treatment Key Points Ref.
Antiphospholipid
syndrome
Pregnant mice Human IgG containingaPL antibodies
Antibodies or peptides that block C5a-C5a receptor interactions prevent pregnancy
complications. [8]
Non-pregnant
mice
IgG-APS/rEV576
(treatment group) and
IgG-APS/phosphate
buffer (controls)
Mice treated with IgG-APS/rEV576 [(coversin), a recombinant protein inhibitor of complement
factor 5 activation] had significantly smaller thrombi than those treated with
IgG-APS/phosphate buffer. This confirmed involvement of complement activation in
antiphospholipid antibody-mediated thrombogenesis and suggested that this effect might be
ameliorated by complement inhibition.
[9]
Pregnant woman
(case report) Eculizumab
Triple positive aPL. Multiple previous arterial thromboses and ongoing ischemia during
pregnancy. Significant risk of catastrophic APS. Eculizumab was administered twice before
cesarean section which was performed at 32+4 gestational weeks with the birth of a heathy child.
Complement activity surprisingly increased to normal levels within a week after both doses of
eculizumab despite the evidence of complete inhibition of complement activity after each
infusion. Pregnancy may influence pharmacodynamics and pharmacokinetics of eculizumab.
Individual approach suggested.
[10]
Pregnant woman
(case report) Eculizumab
Triple positive aPL. Abruptly developed microangiopathic hemolytic anemia, renal insufficiency,
and thrombocytopenia at 30+6 weeks despite treatment with ASA, LMWH and
hydroxycholoquine. Eculizumab was administered and pregnancy was safely continued for 9
days. The second eculizumab infusion was administered a week after the first treatment with
rapid normalization of platelet count, renal function and hemoglobin level.
[11]
Sickle-cell disease
Patients with
thrombotic
microangiopathies
Eculizumab
Increased complement activation was demonstrated in a portion of patients, especially older
patients and those with higher HbS levels. In vitro study on the efficacy of complement
inhibition by eculizumab in the modified Ham test. Mixing eculizumab-containing serum with
complement-activated sera abolished complement-mediated cell killing in a dose-dependent
relationship that was consistent across the three patients tested.
[12]
SCD patient who
developed aHUS
(case report)
Eculizumab
Respiratory and renal insufficiency unresponsible to plasmapheresis successfully treated with
eculizumab. A clear evidence of complement activation was demonstrated by increased levels of
sC5b-9 levels retrospectively analyzed from stored plasma prior to plasmapheresis. After
eculizumab treatment and improvement of clinical symptoms and laboratory baseline, sC5b-9
levels normalized. This case demonstrated that patients with SCD may develop
complement-mediated thrombotic microangiopathy i.e., aHUS, particularly when an underlying
genetic defect in complement regulation is present.
[13]
Pregnant woman
(case report) Eculizumab
A pregnant woman with HbSS who presented with hyperhemolysis at 25 gestational weeks and
worsening anemia despite methylprednisolone and immunoglobulin treatment. Eculizumab
treatment resulted in resolution of the hemolysis, with safe delivery at 34 weeks of gestation.
[14]
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Table 1. Cont.
Disease Subject(s) Treatment Key Points Ref.
HELLP syndrome
Sixteen pregnant
women with
HELLP
N/A Incresed complement activation demonstration in sera. [15]
Pregnant women
with HELLP N/A
Increased complement activation was observed in participants with classic or atypical HELLP
compared with those with normal pregnancies and nonpregnant controls. Mixing HELLP serum
with eculizumab-containing serum resulted in a significant decrease in cell killing compared with
HELLP serum alone. Data of this study demonstrated striking similarities between HELLP and
aHUS.
[16]
Pregnant women
with HELLP (case
report)
Eculizumab
Prolongation of pregnancy from 26+3 to 28+6 (17 days) was achieved. In this case, reduction of
soluble C5b-9 in plasma and urine correlated with clinical improvement, and resolution of
hemolysis, thrombocytopenia and liver inflammation along with a prolonged pregnancy.
[17]
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2. Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a clinical condition characterized by recurrent thrombosis
and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). It is well-acknowledged
that pregnant women with APS are an extremely high-risk group for adverse outcome affecting mother,
fetus, and a newborn, including early miscarriage, stillbirth, fetal growth restriction, neonatal asphyxia,
and prematurity with consequent serious perinatal mortality and morbidity. The study of Jeremic
et al. [18] that included 55 pregnant women with APS reported pregnancy loss and prematurity
rates of 18.2% and 31.8%. Also, significantly more patients with APS experienced thrombocytopenia,
pregnancy losses, intrauterine growth restriction, preeclampsia, and perinatal asphyxia compared with
the control group that included 55 heathy pregnant women. Similar results were obtained in other
cohorts of different sizes [19–22].
At present, therapy of pregnant women with APS is based on preventing thrombosis by
acetylsalicylic acid (ASA) and/or low molecular weight heparin (LMWH), but anticoagulation is
only partially successful in decreasing adverse pregnancy outcomes.
The PREGNANTS study [19] reported an increased risk of obstetric complications and lower
live birth rate when more than one antiphospholipid antibody is present in women with primary
antiphospholipid syndrome. Additionally, the study showed that despite therapy with low-dose ASA
and prophylacticLMWH, the chance of a liveborn neonate was only 30% for triple-positive women.
There is an emerging experimental and clinical evidence supporting the role of complement
cascade activation in the underlying pathophysiology of aPL-induced pregnancy loss and thrombosis.
Girardi et al. hypothesized that complement activation is a central mechanism of pregnancy loss
in APS [8]. They tested this in pregnant mice that received human IgG containing aPL antibodies.
Complement component C5 (and particularly its cleavage product C5a) and neutrophils were reported
to be key mediators of fetal injury. It was demonstrated that antibodies or peptides that block C5a-C5a
receptor interactions prevent pregnancy complications. Based on their results, authors conclude
that identifying complement-related markers that predict high risk for fetal loss would enable us to
translate knowledge about the mechanisms of complement-mediated disease into complement-targeted
therapeutics that may prevent, arrest, or modify the deleterious effects of aPL antibodies.
Romay-Penabad et al. [9] examined the effects of rEV576 (coversin), a recombinant protein
inhibitor of complement factor 5 activation, on APL antibody-mediated tissue factor up-regulation and
thrombosis in non-pregnant mice by administering either IgG from a patient with antiphospholipid
syndrome (APS) or control IgG from normal human serum. Animals treated with IgG-APS had
significantly higher titers of anticardiolipin antibodies and anti-β2GPI and showed significantly larger
thrombi compared with other groups. On the contrary, mice treated with IgG-APS/rEV576 had
significantly smaller thrombi than those treated with IgG-APS/phosphate buffer. The results of this
research confirmed involvement of complement activation in antiphospholipid antibody-mediated
thrombogenesis and suggested that this effect might be ameliorated by complement inhibition.
There are only two case reports on eculizumab use in pregnant women with APS. Gustavsen et al. [10]
reported in details a case of 22-year- old primigravida with triple positive aPL antibodies and a history
of arterial thrombosis treated with by-pass grafting and digital amputations. Additionally, recurrent
episodes of thrombosis were treated with percutaneous transluminal angioplasty, and an episode of
microemboli resolved with intensified anticoagulant treatment that continued during the pregnancy.
She was admitted in the third trimester with painful ulcerations of ischemic origin in her right leg. Due
to multiple previous arterial thromboses and ongoing ischemia during pregnancy, it was estimated
that the risk of developing catastrophic APS in relation to pregnancy, delivery, and puerperium was
significant. Eculizumab was administered twice: 600 mg 8 days before delivery (day 0) in addition to
prophylactic antibiotics and thereafter a 2nd dose of 600 mg was infused on day 7. The following day
(day 8), at 32+4 gestational weeks, cesarean section was performed with the birth of a healthy child.
In this case, complement activity surprisingly increased to normal levels within a week after
both doses of eculizumab despite the evidence of complete inhibition of complement activity after
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each infusion. Authors speculate that pregnancy-induced changes might have influenced the
pharmacodynamics and pharmacokinetics of eculizumab. The lesson learnt from this report is that
an individual approach to the complement inhibition and adequate monitoring of the treatment
effects should be implemented to enable optimal dosage and duration of eculizumab treatment in
such patients.
Rovere-Querini et al. [11] described a pregnant woman who had previous thrombotic events,
a history of abortions, and triple persistent positivity for aPL and abruptly developed microangiopathic
hemolytic anemia, renal insufficiency, and thrombocytopenia at 30+6 weeks of pregnancy despite
previous treatment with rituximab and current treatment with hydroxycholoquine, therapeutic dosage
of LMWH along with low dose ASA. The onset of severe clinical situation was precipitated by acute
hemorrhage from a vulvar angiokeratoma. In less than a week, hemolysis, thrombocytopenia, and
renal functions worsened despite continuous infusion of antithrombin III concentrate. The patient
had clear laboratory evidence of C3 activation. Eculizumab was administered and pregnancy was
safely continued for 9 days after which cesarean section was performed due to the fall of platelet
count. A healthy baby with favourable outcome was born. The second eculizumab infusion was
administered a week after the first treatment with rapid normalization of platelet count, renal function,
and hemoglobin level.
Authors concluded that eculizumab represented a worthy addition to the existing treatment
regimen, which may prevent the rapid deterioration of clinical conditions and enable safe pregnancy
prolongation for reasonable and clinically relevant period as well as enable safe and rapid recovery
from pregnancy.
Women with APS receiving intense anticoagulant therapy are at increased risk for peri- and
postpartum hemorrhage. On the other hand, cesarean section and cessation of anticoagulant treatment
would considerably increase the risk of triggering catastrophic APS. Introduction of eculizumab in
these cases seems biologically justified and plausible.
3. Sickle-Cell Trait/Anemia/Disease
Sickle cell disease (SCD) is a serious and painful disease with the consequent significant morbidity
and mortality. Also, pregnancy in a patient with SCD is associated with high maternal and fetal
morbidity and mortality; the maternal and fetal death rates have been reported to be as high as
20% [23,24].
Renal involvement in patients with asymptomatic and manifest SCD is frequent with proteinuria
as a common feature of sickle-cell nephropathy (SCN), which may progress to renal insufficiency and
end stage renal disease [25]. A systematic review and meta-analysis [26] which included the pooled
sample size of more than 26,000 pregnancies in women with SCD showed a strong association between
SCD and adverse outcome for both mother (including maternal mortality and pre-eclampsia) and
fetus/newborn (perinatal death, preterm delivery, and small for gestational age infants). The recent
extensive review of the current literature regarding pregnancy outcome of women with sickle-cell
anemia showed high maternal mortality, particularly in the intra-and post-partum periods [27]. It has
been demonstrated that both maternal and fetal mortality may be reduced by improvements in
transfusion policy.
Knowledge of these risks has contributed to the implementation of a multidisciplinary
management of such pregnancies including the early detection and treatment of pregnancy and
postpartum complications, follow-up, appropriate pain management protocols, and individual blood
transfusion programs to each pregnant patient. However, no prospective controlled trials have
been conducted.
An important component of hemolysis in SCD mechanism may also be complement activation,
which is a rather neglected entity in SCD. The first reports of complement activation in patients with
asymptomatic [28,29] and symptomatic patients [30] with sickle-cell anemia have been published
almost four decades ago. Most of the publications has been investigating C3 complement component.
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After the relative paucity of investigations regarding complement activation role in SCD, the recent
publications rebooted this issue.
Gavriilaki et al. [12] studied for the first time novel markers of SCD that have been shown to
reliably detect complement activation in the serum of patients with thrombotic microangiopathies [12].
Increased complement activation was demonstrated in a portion of patients, especially older patients
and those with higher HbS levels. They evaluated in vitro the efficacy of complement inhibition by
eculizumab in the modified Ham test and demonstrated that mixing eculizumab-containing serum
with complement-activated sera abolished complement-mediated cell killing in a dose-dependent
relationship that was consistent across the 3 patients tested. Also, soluble C5b-9 levels were significantly
increased compared to normal human serum suggesting that complement dysregulation might be
an additional factor in the complex pathophysiology of SCD in steady state. Similarly, Chapin et al.
reported increased soluble C5b-9 levels in patients with SCD [31].
Chonat et al. reported atypical hemolytic uremic syndrome in a patient with sickle-cell disease
with respiratory and renal insufficiency unresponsive to plasmapheresis successfully treated with
eculizumab [13]. The patient showed clear evidence of complement activation demonstrated by
increased levels of sC5b-9 levels retrospectively analyzed from stored plasma prior to plasmapheresis.
After eculizumab treatment and improvement of clinical symptoms and laboratory baseline, sC5b-9
levels normalized. Additionally, sequence analysis of the complement regulatory genes revealed
a heterozygous mutation of CFB (c.724A>C, p.I242L), previously reported to be associated with
aHUS [32].
This case demonstrated that patients with SCD may develop complement-mediated thrombotic
microangiopathy i.e., aHUS, particularly when an underlying genetic defect in complement regulation
is present. The obvious benefit of eculizumab clearly emphasized the pathogenicity of complement
activation in this rare disease.
The only report of use of eculizumab for the management of hyperhemolysis in pregnancy in
sickle cell disease was published by Kirui et al. [14]. This case report described a pregnant woman
with HbSS who presented with hyperhemolysis at 25 gestational weeks, seven days after a red cell
transfusion for a vaso-occlusive crisis. Her anemia was worsening despite methylprednisolone and
immunoglobulin treatment. Eculizumab treatment resulted in resolution of the hemolysis, with safe
delivery at 34 weeks gestation. Authors suggest that eculizumab should be accessible and considered
in severe cases of hyperhaemolysis which are refractory to standard treatment in pregnant women
with SCD refractory to conventional therapy.
A systematic review of clinical outcomes associated with sickle cell trait (SCT) revealed a positive
association between SCT and chronic kidney disease among other adverse health outcomes, such as
pulmonary embolism and other complications [33].
Despite of some improvement in the management, SCD remains a serious disease with high
mortality rate [34]. Early recognition of patients with increased complement activation may facilitate
prompt intervention. Prospective studies are needed to better understand the role of complement in
the pathophysiology and therapy of SCD.
4. HELLP Syndrome
HELLP syndrome (Hemolysis, ELevated liver enzymes, and Low Platelets) is usually considered
as a severe variant or continuum of pre-eclampsia and is observed in 0.8% of all pregnancies. HELLP
complicates 10% to 20% of pregnancies with pre-eclampsia but may also occur without it.
Although the exact pathogenesis of HELLP still remains obscure, it is usually believed that
abnormal placentation, endothelial dysfunction, and release of vasoactive substances in the first
trimester are the main etiological factors [35]. Interestingly, alternative pathway of complement
activation coincides with the critical weeks of placentation [36].
Qing et al. showed that targeted inhibition of complement activation prevents features of
preeclampsia in mice by prevention of oxidative stress and placental dysfunction [37].
J. Clin. Med. 2019, 8, 407 8 of 20
A small cohort of 16 women with HELLP syndrome treated at academic tertiary care demonstrated
complement activation in 9 laboratory parameters [15]. Interestingly, in the majority of cases, classical
pathway of complement activation identified by a decrease in C4 levels was predominant. Furthermore,
one of the pregnant women was diagnosed with APS and 5 patients had a partial expression deficiency
of CD 55, which regulates and block the complement membrane attack complex. Of note, CD 55
expression deficiency is commonly used as a marker of PNH.
The study of Ma et al. showed increased C5a deposition in macrophages and C5a receptor
(C5aR) expression in trophoblasts of pre-eclamptic placentas compared to placentas from normal
pregnancies [38]. They also demonstrated that maternal C5a serum level was increased in women
with pre-eclampsia and was positively correlated with maternal blood pressure and arterial
stiffness. Authors conclude that the placental C5a/C5aR pathway contributed to the development of
pre-eclampsia by regulating placental trophoblast dysfunction. Hypothesising that HELLP syndrome is
a 2-hit disease similar to, requiring both genetic susceptibility [39,40] and an environmental risk factor,
Vaught et al. demonstrated with the modified Ham assay that HELLP syndrome is associated with
increased alternative component of complement activation [16]. This study also reported that mixing
HELLP serum with eculizumab-containing serum resulted in a significant decrease in cell killing
compared with HELLP serum alone. Authors thus suggest the modified Ham test as a promising
tool to identify patients with increased complement activation who might benefit from complement
activation blockade. Data of this study demonstrated striking similarities between HELLP and aHUS.
There are several retrospective cohort studies reporting perinatal and neonatal outcome in
pregnancies with HELLP. Gul et al. reported in the cohort of 367 consecutive severe pre-eclampsia
(29% of which had HELLP syndrome) that perinatal mortality and neonatal morbidity and mortality
were similar in HELLP syndrome compared with severe preeclampsia-eclampsia without HELLP [41].
However, overall fetal mortality was higher in HELLP syndrome with no regular prenatal care.
In HELLP group there were 10.3% stillbirths and perinatal mortality was 16.8%.
A retrospective cohort study of Roelofsen et al. investigated maternal-fetal outcome of infants
born after pregnancies complicated by (H)ELLP syndrome [42]. Total perinatal mortality was 17.6%.
After 18 months, four infants had major handicaps, making a total adverse outcome of 22.8%. This
study demonstrated that early gestational age influenced outcome of the infants most.
Another cohort of 126 cases pregnancies with HELLP was reported by Erdemog˘lu et al. showed
that the stillbirth rate was 14.2% and 11.9% of infants died in the early neonatal period [43]. Of note,
acute renal insufficiency complicated early neonatal period in 11.1% and a very high maternal mortality
rate was reported (8%).
The retrospective study from Thailand on cohort of 213 preeclamptic women (7.5% with HELLP)
demonstrated the stillbirth rate of 1.4% in severe preeclampsia and HELLP [44]. Intrapartum death rate
was also considerably high in the HELLP group (6.4%) but with no statistical significance compared to
women with mild preeclampsia.
Kim et al. investigated neonatal outcome after preterm delivery with HELLP and compared it to
those of pregnancies with preterm preeclampsia and normotensive preterm pregnancies [45]. They
reported 19.5% of neonatal deaths compared to 2% in the group of normotensive subjects. There were
none stillbirth in the normotensive group, but 4.8% rate of stillbirth was reported in the HELLP group.
Hungarian cohort of 50 pregnancies with HELLP showed the incidence of premature birth of
40.7% and 7.4% neonatal mortality rate [46]. Additionally, this study showed that pregnancies with
history of previous HELLP syndrome carry substantial risk for HELLP syndrome recurrence and also
the development of chronic hypertension.
Furthermore, there is an increased subsequent risk of chronic kidney disease (CKD) associated
with hypertensive disorders. Women with pre-eclampsia were also found to have CKD earlier than
normotensive women [47].
Although the expectant care in pregnancies with HELLP may gain few days and slightly improve
the neonatal outcome, it is associated with severe maternal complications. In most of the cases, prompt
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delivery is indicated [48]. The HELLP syndrome is associated with pregnancy-related acute kidney
injury (Pr-AKI) in 7% to 36% of cases, and is often mistakenly classified as a preeclampsia/eclampsia
continuum, even though 20% of cases do not have antecedent hypertension or proteinuria as
essential criteria for these pregnancy disorders [3,35]. Although Pr-AKI shows decreasing incidence
in developing countries, recent reports showed increased incidence in Canada and USA [49,50].
The reason may be not only increasing sensitivity of AKI diagnosis with close obstetric care, especially
in high risk pregnancy, but may also be attributed to factors such as older maternal age, increased
proportion of pregnancies with pregnancies with hypertensive disorders, and women who decide to
conceive despite of underlying chronic kidney disease.
HELLP syndrome is a leading cause of P-AKI that occurs in up to 15% of cases of HELLP syndrome.
AKI associated with HELLP syndrome, even in its severe forms requiring dialysis, is usually transient
However, 10% of patients, especially those with pre-existing hypertensive or renal disease, progress to
CKD [35,51,52]. HELLP syndrome shares complement gene mutations with aHUS and both conditions
are characterized by elevated C5a and C5b-9 levels [53].
There is only one well-documented case report on eculizumab use in pregnancy with HELLP,
although it has not been officially approved for this indication [17]. Prolongation of pregnancy
from 26+3 to 28+6 (17 days) was achieved. In this case, reduction of soluble C5b-9 in plasma and
urine correlated with clinical improvement, and resolution of hemolysis, thrombocytopenia and
liver inflammation [54,55] along with a prolonged pregnancy. A conference abstract from the same
institution [56] as the previous case report included also another patient with preeclampsia associated
HELLP, whose clinical symptoms and laboratory parameters showed dramatic improvement after
single eculizumab dose. The pregnancy was prolonged for three days. Cesarean section was done due
to stable thrombocytopenia. This report is lacking details, so only one well-documented case in the
literature remains.
There is a considerable improvement in neonatal outcome for each week of gestation in
this group of patients, especially when timing of antenatal steroids and magnesium sulphate
neuroprotection is optimal [57,58]. It may be possible that in the near future, eculizumab will be
a drug of choice for selected pregnant women with the clear signs of complement activation in
severe pre-eclampsia/HELLP. Its use may be particularly helpful among women with mutations in
complement regulatory proteins, which are found in 8–18% of women with severe preeclampsia [59].
5. Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria is a rare acquired stem-cell clonal disease that results
from uncontrolled complement system activation characterized mostly by the intravascular hemolysis.
Paradoxically, PNH name is actually incorrect; hemolysis is constant, not paroxysmal, it does not occur
only during night and most of the patients do not have hemoglobinuria. A somatic mutation of the
PIG-A gene in the hematopoietic stem cells leads to a deficiency in the glycosylphosphatydilinositol
(GPI) membrane-anchoring proteins CD55 and CD59 that are complement inhibitors and makes
PNH erythrocytes susceptible to the complement-mediated lysis [60]. As a result of free hemoglobin
generation and depletion of nitric oxide, vasoconstriction and platelet activation occur [61]. The precise
incidence of PNH has not been well-documented, but it is estimated to be 1.5 to 2 cases per million
of the population per year [62]. The incidence during pregnancy is not known. PNH represent
serious prothrombotic condition with severe renal insufficiency and life-threatening multiple organ
failure. Patients with PNH have six-fold greater risk of chronic kidney disease compared to the
general population, which is contributing to the premature mortality and contributes to up to 18% of
PNH-related deaths [61–63]. Until recently, the treatment of PNH was mainly supportive including
blood transfusions, anabolic steroids and corticosteroids along with the thrombosis prophylaxis.
An allogenic hematopoietic transplant reserved for selected patients [64].
The development and approval of eculizumab that inhibits terminal complement activation
changed the treatment landscape dramatically with the improvement of quality of life and overall
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survival. One of the largest single institution cohorts of patients with PNH was described in Spanish
study with 56 patients recruited within 40 years, 16 of which have been treated with eculizumab [65].
The median survival rate of the patients from the beginning of the follow-up was only 11 years. Of 16
patients treated with eculizumab none has presented clinically relevant infection. There were not
eculizumab-treated pregnant women with PNH in this cohort. The prevalence of renal failure in the
whole cohort was high varying from 14% in subclinical form of disease to 44.8% in those with classic
PNH. Eculizumab appeared as a safe drug in this case series of 16 patients, provided improvement
in the patients’ quality of life and the disappearance of clinical symptoms. The efficacy and safety
of the eculizumab treatment in PNH was demonstrated in the double-blind randomized controlled
trial (TRIUMPH) [66] and open-label, non–placebo-controlled SHEPHERD study on the broader PNH
population [67]. Of special interest, eculizumab particularly improved a renal function in patients
with PNH, especially if administered early in the course of disease before the kidney is more severely
impaired. The same results were demonstrated in a retrospective analysis from the Spanish PNH
registry including 128 patients [68]. Authors concluded that treatment with eculizumab in PNH has
a beneficial effect on renal function, preventing acute renal failure and progression to chronic renal
failure [68].
Apart from the dramatical improvement in clinical symptoms of the patients with PNH,
the treatment with eculizumab also improved nearly all aspects of the quality of life. Long-term
safety and efficacy data on eculizumab have been reported by two studies [63,69]. Both studies yielded
similar results and generally demonstrated that eculizumab was well tolerated, with no evidence of
cumulative toxicity and a decreasing occurrence of adverse events over time. Al-Ani et al. reviewed
some special considerations pertaining to the use of eculizumab in PNH [70].
From the historical perspective, pregnancy has been discouraged in patients with PNH due to
the extremely high rate of adverse outcomes including maternal mortality in up to 20% of cases with
thromboembolism as the major cause of death [6].
Of importance, fetal and neonatal mortality were reported to be as high as 9%, mainly due to
the high rate of extreme prematurity with only half of the pregnancies progressing to the term [6].
Intravascular hemolysis as the key clinical feature of PNH is frequently more severe during the
pregnancy compared to the non-pregnant state and pregnancy itself as a highly thrombogenic state
complicates further the features of this disease.
Data on the use of eculizumab in women during pregnancy are rare. Apart from a dozen of case
reports on the use of eculizumab in pregnant women with PNH, the most comprehensive study of
efficacy and safety of eculizumab in pregnant patients with PNH was carried out by Kelly et al. [71].
This study examined 75 pregnancies in 61 women identified from the International PNH registry. Birth
and developmental records of children were also carried out by the questionnaire. There were no
maternal deaths and three fetal deaths occurred (4%). Requirements for blood transfusions increased
during pregnancy. In 54% of pregnancies, the dose or the frequency of eculizumab treatment had
to be increased, which was expected due to the concomitant physiological increase in complement
activation during the second and especially third trimester. There were no thrombotic events during
pregnancy; two of the thrombotic events were recorded in the postpartum period.
The prematurity rate was 29% which was rather high, but much lower than in the historical
cohorts before the eculizumab era. Neonatal complications were mostly due to the prematurity. There
were no cases of severe neonatal infections. This may be explained partly by the results of our study
which demonstrated that eculizumab treatment does not affect the complement system activity of the
newborn [72]. Eculizumab was not detected in any of the 10 breast-milk samples. Developmental
assessment of children was performed at median age of 31 months in 64 children. Except one child
with slightly delayed speech development, no particular neurodevelopmental problems were observed.
However, proper comparison of pregnancies with PNH treated with eculizumab with those before
eculizumab use is almost difficult due to the potential selection bias and retrospective nature of the
studies published. It is unlikely that randomized trials will be ever conducted due to ethical reasons.
J. Clin. Med. 2019, 8, 407 11 of 20
6. Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening disorder mostly caused
by inherited defects of the alternative pathway of complement characterized by microangiopathic
hemolytic anemia, thrombocytopenia and acute kidney injury. It may occasionally be triggered
by pregnancy (p-aHUS) and is complicating 1:25,000 pregnancies, particularly in the postpartum
period [73,74]. Most of the studies on aHUS included non-pregnant patients, while studies describing
p-aHUS are rare and mostly describe maternal outcomes with little focus on the neonatal outcome.
While Fakhouri et al. reported that the risk for pregnancy-associated aHUS was highest during a
second pregnancy [75], two other studies demonstrated that pregnancy-associated aHUS occured
in majority of cases during the first pregnancy [73,76]. The latter retrospective international study
that included 87 women with p-aHUS revealed the same frequency of complement gene variants and
similar severity at onset and during follow-up as those with aHUS not related to pregnancy. This
study reported that 62% reached end-stage renal disease by 1 month and 76% by last follow-up. None
of the patients received eculizumab. A study of Fakhouri et al. reported no differences in outcomes,
comparing patients with pregnancy- related and non- pregnancy-related aHUS [75]. The Vienna
Thrombotic Microangiopathy Cohort retrospectively and prospectively investigated maternal and
fetal/neonatal outcomes in 27 pregnancies of 14 women with aHUS [77]. While majority of pregnancies
resulted in a term live birth (70%), two preterm live births, two preterm stillbirths and four early
spontaneous abortions before 21 weeks of gestation occurred. Although short-term renal outcome was
good in majority of women, long-term renal outcome was poor with 4/14 women having CKD stage
1-4, 5/14 had received a renal allograft, and 3/14 were dialysis-dependent at the end of this study.
A systematic review of eculizumab for atypical aHUS demonstrated its effectiveness and
long-term safety in the treatment of this disorder [78]. Coffiell et al. evaluated longitudinally the effect
of terminal complement blockade in patients with aHUS with eculizumab by measuring biomarkers
of cellular processes and compared them with those of healthy volunteers [79]. In patients with
aHUS, both with and without identified complement mutations, markers were significantly elevated at
baseline. During ongoing eculizumab therapy, a significant reduction of marker levels in both subsets
of patients was observed. The aforementioned retrospective study from Spain analyzed clinical and
prognostic data of 22 p-aHUS patients under different treatment [73]. Seventeen patients had plasma
treatments with positive renal response in only 3 cases, while 10 patients were treated with eculizumab
with an excellent response.
Historically, management of pregnancy in aHUS patients has been challenging and pregnancy
was discouraged. However, women with aHUS who are receiving eculizumab at present have an
improved quality of life and are more likely to consider pregnancy.
Reports on the use of eculizumab during pregnancy are mostly single case reports [80–82]. The
results of those studies are displayed in a recently published narrative overview of eculizumab use
in pregnancy by Sarno et al. [83]. There was a huge difference in time of commencing eculizumab
treatment, doses, infusion intervals and duration of the therapy. The largest study described six
pregnancies with ongoing eculizumab treatment in three pregnant women [84]. All women had
reduced glomerular function at the beginning of their pregnancies. Although eculizumab treatment
prevented relapse of aHUS in all pregnancies, it did not prevent HELLP syndrome in one patient and
pre-eclampsia in two other patients.
7. Preterm Birth and Its Influence on the Renal Development and Function in Offspring
Preterm birth (PTB), defined as birth before 37 gestational weeks is the leading cause of neonatal
morbidity and mortality [5]. Furthermore, extremely PTB is defined as occurring at less than 28 weeks,
very preterm delivery occurring between 28 and 32 weeks, and moderate to late PTB occurring from
32 through completed 36 weeks. These definitions have important clinical relevance as morbidity and
mortality dramatically increase as the duration of gestation decreases. Also, obstetric management
differs with gestational age.
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According to the mode of onset of delivery, preterm births can be classified as iatrogenic or
spontaneous. Iatrogenic preterm birth is a result of induced labor. Maternal and fetal pregnancy
complications, among them preeclampsia and HELLP as well as rare diseases (PNH, aHUS, APS, and
SCD) are among the reasons for rising prevalence of iatrogenic preterm delivery. Furthermore, due
to the improved neonatal care and survival of extremely preterm infants, the ratio of iatrogenic and
spontaneous preterm birth have been changed during the recent decade [85]. Infants born following
medically indicated preterm birth are at a two-fold higher risk of neonatal mortality as compared with
infants born following spontaneous preterm birth [86].
Stevens et al. examined economic burden of preeclampsia in the United States [87] and
demonstrated that in 2012, the cost of preeclampsia within the first 12 months of delivery was $2.18
billion ($1.03 billion for mothers and $1.15 billion for infants), and was disproportionately borne by
births of low gestational age. Authors demonstrated that a reduction in gestational age by 2 weeks
increased costs for all infants by $1.15 billion. Conversely, mean decrease in costs per infant for each
additional week of gestation was the steepest from 23 to 26 weeks, demonstrated by Manuck et al. [88].
After 25 weeks, the length of stay decreased significantly with each additional completed week of
pregnancy. Among babies delivered from 26 to 32 weeks of gestation, each additional week in utero
reduced the subsequent length of neonatal hospitalization by a minimum of 8 days. Neonatal mortality
was 44% among infants delivered at 23 gestational weeks compared to 12%, 8%, and 2% among those
born at 25, 27, and 28 gestational weeks, respectively. Major morbidity among survivors decreased
from 52% at 26 gestational weeks to 23% at 28 gestational weeks.
These data provided valuable information regarding a spectrum of neonatal outcomes for each
week of completed pregnancy. Considering the cost of eculizumab treatment for aHUS and HELLP,
prolongation of such pregnancies for a few weeks might be also cost-effective.
The population-based study from Finland evaluated the effect of gestational age and prematurity-
related morbidities on hospital costs and cost per quality-adjusted life-year (QALY) during the first
4 years of life [89]. Authors demonstrated that the prematurity-related morbidities were associated
with increased costs in the very preterm population and also that initial hospital stay accounted for
most of the costs. Additionally, prematurity-related morbidities were the most expensive after the
initial hospitalization.
A common feature of extremely premature birth is disruption of organogenesis and arresting in
branching organs. The development of fetal kidneys shares similar patterns with organogenesis of the
lungs, pancreas and vascular tree [90].
Nephrogenesis in the human fetus begins during the sixth week of pregnancy and continues
through the 36th week with the majority of nephron development occurring during the last pregnancy
trimester. Studies in mice have demonstrated that premature birth decreases nephron number and
decreases kidney volume compared to mice born at full gestation with the consequent developing of
CKD with hypertension and albuminuria [91]. Similar results have been obtained in experiments on
nonhuman primate models. Nephrons do not regenerate; so the nephrons present at birth must last a
lifetime. Prematurity causes reduction of nephron endowment with lowering gestational age.
Survivors of extreme prematurity suffer arrested development of organs with reduced nephron
endowment as a consequence of hypoxic-ischemic and nephrotoxic renal insults. Short-term
consequences include electrolyte disbalances, acidosis, and impaired free water handling. These
could potentially result in prolonged respiratory support, growth failure, and suboptimal
neurodevelopmental outcomes in the short term. In later life, subclinical chronic renal insufficiency
may progress even in the asymptomatic survivors [90].
Kidney size and nephron number are known to be reduced in surviving premature infants due
to disruption of organogenesis at a crucial developmental time point. Progressive kidney disease in
individuals born prematurely is multifactorial with involvement of genetic and environmental events
that contribute to the programming of subsequent risks of cardiovascular risks and renal disease.
Nephrotoxic medication further may decrease renal function of premature neonates.
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8. Conclusions and Further Perspectives
Excessive or inappropriate activation of complement is a key factor in many diseases [2,8,12,15,
16,28–32,36–40,54,55,66,67,70,74,79,84,91–94]. Classical complementopathies, such as PNH and aHUS
have been extensively studied and have served as model diseases for the development of targeted
therapy by complement inhibitors.
PNH and aHUS are both diseases caused by mutations with the consequent complement-mediated
cell destruction [40,67,92–94] and renal involvement. Eculizumab has revolutionized the treatment of
these diseases and considerably improved the overall outcome and quality of life with beneficial effect
on the renal function. Additionally, pregnancy of women with such diseases have been discouraged,
but the eculizumab for both prevention of disease exacerbation and treatment of disease-related
complications gave hope for many with the encouraging results on the preservation of the renal
function [78,79].
There is considerable evidence of the involvement of inappropriate complement activation
in certain other diseases that may be life threatening (APS, SCD, HELLP) for both mother and
fetus/neonate. Although scarce, the encouraging results on the off-label use of eculizumab in such
diseases gives a further hope that this complement inhibitor will become a part of treatment protocol.
This would enable safe [17,71,84,95] pregnancy prolongation, lower perinatal mortality, better life
quality and decreased rate of prematurity–related acute and chronic renal failure.
However, not only the very high price of eculizumab, lack of standardized treatment protocols
(dosage, infusion intervals, length and monitoring of therapy) for particular diseases and consensus in
determination of the most suitable complement markers and genetic tests (expensive, time-consuming,
and not immediately available to help guide clinical practice at presentation) are just some of the
obstacles in the rapid implementation of this drug into the clinical medicine for off-label use [2,39].
Apart from the lack of large studies on the use of eculizumab for off label indications, one of the
most important stumbling blocks for the wider use of this drug is its extremely high price. It has been
estimated that the annual treatment cost of eculizumab for aHUS is $700,000. However, despite the
expected cost-effectiveness of eculizumab treatment after kidney transplantation in patients with aHUS
demonstrated by van den Brand et al. [96], total costs for any eculizumab-based treatment regimen
remain high. Authors speculate that price reductions for eculizumab may need to be negotiated in
order to increase its acceptability. None of the markers for aHUS recurrence or treatment response have
been validated in clinical studies. Defining and validation of such markers for aHUS recurrence and
eculizumab treatment response would help fine-tune therapies and will probably result in improved
cost-effectiveness of eculizumab-based treatment strategies [96].
Similar cost-effectiveness analysis for PNH reported that eculizumab may provide substantive
benefits to patients with PNH in terms of life expectancy and quality of life but at a high incremental
cost and a substantial opportunity cost [97].
The nature of rare diseases makes the application of cost-effectiveness analysis difficult.
Furthermore, the evidence on the efficacy of new interventions is usually limited, which, combined
with a lack of long-term natural history data relating to rare diseases and their heterogeneous nature,
makes estimating long-term survival and quality of life problematic.
Of note, possible serious side-effects associated with eculizumab treatment may be life-threatening,
limit its use or cause discontinuation of the therapy. The most common side-effect is a headache
that is experienced in more than one in ten patients receiving eculizumab. Serious complications
(meningococcal infections, sepsis, peritonitis) are uncommon (≥1/1000 to <1/100) but life-threatening.
Prior to initiating eculizumab therapy, it is recommended that PNH, and aHUS patients initiate
immunizations according to current immunization guidelines. Additionally, all patients must be
vaccinated against meningococcal infections at least 2 weeks prior to receiving eculizumab unless the
risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection.
Patients who initiate eculizumab treatment less than 2 weeks after receiving a meningococcal vaccine
must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination [98,99].
J. Clin. Med. 2019, 8, 407 14 of 20
However, infectious morbidity of pregnant women treated with eculizumab is not alarming. Data on
75 pregnancies in 61 women with eculizumab-treated PNH reported two cases of postpartum sepsis
and no cases of serious neonatal infectious morbidity [71]. The latter may be partially explained by
the fact that eculizumab treatment during pregnancy does not affect the complement system activity
of the newborn [72]. It is plausible to conclude that meningococcal vaccine is recommended also
for all patients on eculizumab for off-label indications. Potential medico-legal issues should not be
neglected either.
Concerning rarity of such diseases, especially during pregnancy, one of the steps to gain more
knowledge would be International registries of case-reports and well-designed multicenter trials.
Unless the pharmaceutical industry recognizes the potential gold mine, particularly in preeclampsia
/HELLP (with the incomparably higher incidence than the other diseases discussed in this review)
and provide a financial support for the further research and hopefully authority approval, it may
be possible that the high price will remain the main obstacle for future progress (Figure 2). Similar
concerns appear also for potential extended use of eculizumab for off-label indications in non-pregnant
patients, as well.
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Figure 2. Essential steps before potential extended use of eculizumab in complement-associated
diseases in pregnancy.
More research is urgently needed to develop new treatments and preventive modalities,
particularly in pregnancies complicated by maternal preexisting comorbidities and risk factors
for kidney injury that show increasing prevalence in the developed countries. Development
of precise complement functional and genetic studies with rapid turnaround time is urgently
needed [39,95,100,101].
By potentially preventing extremely preterm birth, one of the most devastating pregnancy
complications, eculizumab might also in this way decrease the risk of chronic kidney disease and
cardiovascular diseases of the offspring. Multidisciplinary teams should be involved not only
in pregnancy planning of women with preexisting chronic diseases associated with complement
activation, but also in treatment of complications in such pregnancies [39,95,100,101].
Of note, several novel drugs have been recently developed for blocking the complement cascade,
including purified plasma proteins (purified factor H, C1 inhibitor) new monoclonal antibodies
(Anti-C1s, Anti-factor D), recombinant proteins (complement receptor 1 and targeted complement
regulatory proteins), small molecules (e.g., compstatin), and small interfering RNA agents [102].
We hope that the use of eculizumab for extended indications during pregnancy will be a reality in the
near future.
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